134 related articles for article (PubMed ID: 7545218)
1. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
2. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
[TBL] [Abstract][Full Text] [Related]
6. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
7. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
[TBL] [Abstract][Full Text] [Related]
8. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
10. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
11. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
12. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
13. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
14. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
18. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
19. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
Small EJ; Frohlich MW; Bok R; Shinohara K; Grossfeld G; Rozenblat Z; Kelly WK; Corry M; Reese DM
J Clin Oncol; 2000 Nov; 18(21):3595-603. PubMed ID: 11054432
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]